Detalhe da pesquisa
1.
Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.
Transfusion
; 58(2): 413-422, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194665
2.
Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients.
J Thromb Haemost
; 18(4): 815-824, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31885190
3.
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
N Engl J Med
; 348(15): 1425-34, 2003 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-12601075
4.
Use of objective efficacy criteria for evaluation of von Willebrand factor/factor VIII concentrates.
Blood Coagul Fibrinolysis
; 23(4): 262-7, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22322140
5.
The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Thromb Haemost
; 106(2): 279-88, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21725579
6.
Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.
Transfusion
; 42(2): 190-7, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11896334